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Although traditionally fresh frozen plasma (FFP) has been the product of choice for revers-
ing a significant coagulopathy, the modern blood bank will have several different plasma 
preparations which should all be equally efficacious in reversing a significant coagulop-
athy or arresting coagulopathic bleeding. Emerging evidence suggests that for a stable 
patient, transfusing plasma for an INR≤1.5 does not confer a hemostatic benefit while 
unnecessarily exposing the patient to the risks associated with plasma transfusion. This 
review will discuss the various plasma products that are available and present some of 
the current literature on the clinical uses of plasma.
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COMMON PLASMA PRODUCTS
  There are numerous plasma products listed in the circular 
of information for the use of human blood and blood compo-
nents, a joint effort of the AABB (formerly known as the 
American Association of Blood Banks), the America’s Blood 
Centers, the FDA and the American Red Cross [1]. This 
short review will focus on the most commonly used plasma 
components, fresh frozen plasma (FFP), thawed plasma (TP), 
and plasma frozen within 24 hours after phlebotomy (FP24). 
As the clotting factors in these products are nearly equivalent, 
the generic term “plasma” will be used throughout this 
review.
  FFP is prepared from whole blood donations or is collected 
by plasmapheresis, and in 2006 it accounted for about 77% 
of all plasma transfused in the USA [2]. To be labeled as 
FFP, the plasma must be frozen at -18
oC or less within 
8 hours of collection [3]. By definition FFP contains 1 IU/mL 
of all clotting factors. There is, however, variability in coagu-
lation factor levels as demonstrated in a study looking at 
the INR of 20 units of FFP; the mean INR was 1.1 while 
the range was 0.9-1.3 [4]. This could have ramifications 
if plasma units with relatively higher INRs are used to try 
to reverse a recipient’s mildly elevated INR (see below).
  F F P  i s  s t o r e d  a t  - 1 8
oC or less for up to 1 year [3]. It 
is thawed in a 30-37
oC water bath generally when an order 
for transfusion is received by the blood bank and this step 
normally takes 20-25 minutes. Once thawed, the FFP can 
be kept at 1-6
oC for up to 24 hours without significant loss 
of clotting factors. If the FFP is not used within 24 hours, 
it must either be discarded or relabeled as thawed plasma 
(TP).
  TP is the product that can result if liquid plasma is main-
tained at 1-6
oC for more than 1 day; once FFP has been 
thawed and refrigerated for more than 24 hours, it can no 
longer be labeled as “fresh frozen” plasma. Instead the thawed 
unit can be relabeled as TP, and it can continue to be stored 
in the liquid state at 1-6
oC for up to 4 more days [3]. A 
recent study demonstrated that for both leukoreduced apher-
sis or whole blood plasma stored in the liquid state between 
2-6
oC, the level of factor VIII decreased to approximately 
0.40 IU/mL at 28 days of storage [5]. Other studies of TP 
prepared from FFP demonstrated approximately 14-55% de-
creases in factor VIII levels at day 5 of storage compared 
to day 1 [6, 7], but these residual levels, including that of 
ADAMTS-13 after 5 days of storage, were still well within 
the therapeutic range [8-10]. The decreases in factor V levels 
were smaller [6, 8] even after 28 days of storage [5]. TP 
has the advantage of already being in a liquid state thus 
eliminating the time delay caused by thawing the frozen 
FFP, and it effectively extends the shelf-life of a unit of Korean J Hematol 2010;45:152-7.
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Fig. 1. Theoretical relationship between concentration of coagulation 
factors and PT/INR. Based on the experience with single factor 
deficiencies, coagulation proceeds normally until the concentration of 
factors drops below 30%. Thus there is a significant reserve of clotting 
factors (the physiologic reserve). Also note that abnormal clotting times 
can occur while the levels of clotting factors are still within the 
physiologic reserve, another reason why the PT/INR does not 
necessarily predict peri-operative bleeding. Refer to text for explanation 
of the labels. Modified and reprinted from reference [23], with 
permission from the AABB.
Fig. 2. PT values in healthy individuals who first received oral anti-
coagulation, then 1 L of autologous plasma, then oral vitamin K at the
end of the study. Note how the FFP produced only a partial correction
of the elevated PT (B) while the vitamin K completely reversed the 
coagulopathy (D). The therapeutic effect of FFP lasted for approxi-
mately 7-8 hours (C). Refer to text for explanation of the labels. 
Modified and reprinted with permission from the AABB from reference
[19]. ◇ (green line), mean test infusion; x (purple dotted line), mean 
control infusion; bars represent 95% CIs.
plasma that would otherwise have been discarded, thereby 
reducing wastage of a limited resource.
  In an effort to reduce the risk of transfusion related acute 
lung injury (TRALI) from plasma components, many blood 
centers have limited the collection of plasma from female 
donors due to their propensity for developing anti-HLA al-
loimmunization after pregnancy [11]. To avoid a shortfall 
in the plasma supply, there is increasing reliance on the 
production of plasma from male whole blood donations that 
have been stored between 8-24 hours prior to freezing. This 
product is known as plasma frozen within 24 hours after 
phlebotomy (FP24) and in 2006 it accounted for approx-
imately 15% of all the plasma transfused in the USA [2]. 
The levels of most clotting factors are not significantly dimin-
ished compared to regular FFP at the time of thawing [7, 
12-15], and recently 2 studies have demonstrated that the 
levels of clotting factors remain hemostatic during 5 days 
of refrigerated storage of TP prepared from FP24 [16, 17]. 
In one study the levels of V and VIII declined to means 
of 59 and 48 IU/dL [17], respectively, on storage day 5, 
and in the other study the level of protein S (PS) was slightly 
below the reference range by day 5 [16]. These minor changes 
are unlikely to be clinically significant. Recently Alhumaidan 
et al. demonstrated that FP24 could be prepared from either 
platelet rich plasma or whole blood donations and stored 
for up to 7 days at refrigerator temperatures with main-
tenance of clotting factors at clinically adequate levels [18]. 
It should be noted, however, that the only currently AABB/ 
FDA approved starting material for TP is FFP [3]. Further-
more, neither FP24 nor the TP products have been directly 
compared to FFP in terms of their efficacy in reversing 
coagulopathies or arresting coagulopathic bleeding, however 
based on the well preserved coagulation factors there is no 
a priori reason why these products would be inferior to 
FFP.
ADMINISTRATION OF PLASMA
  T h e g en eral l y cit ed  do s e o f  pl asma r eq uire d t o  r ev er se 
a coagulopathy is 10-15 mL/kg. In many institutes, the 
threshold for transfusing plasma is an INR≥1.6. When the 
INR starts to exceed 1.6, factor levels begin to drop below 
30% which for many of them is the threshold for normal 
hemostasis (Fig. 1, point A). Factor VII has a short half 
life (4-6 hours) thus if plasma is administered more than 
8-10 hours before the planned procedure, it will have gone 
through at least 2 half-lives thus reducing its hemostatic 
efficacy at the time of surgery. Fig. 2, point A indicates 
the time at which plasma was reinfused to healthy volunteers 
who had been orally anticoagulated as part of a study protocol 
(see below for further details) [19]. Approximately 8 hours 
after the plasma infusion (point C) the PT began to rise 
steeply reflecting the end of the plasma’s efficacy. Thus trans-
fusing plasma as close to the time of an invasive procedure 
as possible will produce its maximum hemostatic efficacy. 
O n  t h e  o t h e r  h a n d  o n c e  p l a s m a  i s  t r a n s f u s e d  i t ,  l i k e  a l l  
blood products, it remains almost entirely in the intravascular 
space; unlike crystalloids that distribute themselves between 
the intra- and extra-vascular spaces, plasma remains nearly 
entirely in the circulation. This needs to be borne in mind 
because rapid infusion rates, intended to facilitate the admin-Korean J Hematol 2010;45:152-7.
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istration of the entire dose of plasma before the start of 
the surgery, could lead to circulatory (volume) overload.
USE OF PLASMA
  The use of plasma in the USA is growing. In 2006 approx-
imately 4 million units were transfused [2], which is several 
orders of magnitude higher than in several other developed 
countries [20]. The indications for plasma transfusion include 
reversal of a significant coagulopathy in a bleeding patient 
or one who is about to undergo a surgical procedure, bleeding 
in the setting of multiple factor deficiencies, or in the rare 
patient with a deficiency of a factor for which there is no 
viral-inactivated/recombinant concentrate available. Neither 
its use as a replacement fluid for therapeutic aphersis in 
thrombotic thrombocytopenic purpura (TTP) patients, nor 
the pharmacological procoagulant agents (such as rfVIIa) 
that might also be used to reverse a significant coagulopathy 
will be discussed in this report. The use of plasma as part 
of fixed ratio RBC: plasma protocols for the resuscitation 
of trauma patients is controversial and is extensively re-
viewed in reference [21]. Often times the question facing 
the clinician when trying to decide whether to transfuse 
plasma is: When is a coagulopathy significant enough for 
the benefits of plasma transfusion to outweigh its potential 
adverse events such as TRALI and volume overload? 
  To answer this question, 2 important meta-analyses have 
been performed. Segal and Dzik analyzed 25 studies of var-
iably coagulopathic patients undergoing a variety of minor 
procedures including liver biopsy, kidney biopsy, central 
vein cannulation, paracentesis and others and asked the ques-
tion, does the peri-operative PT/INR predict the risk of major 
bleeding during these procedures [22]? The vast majority 
of the reports included in this meta-analysis were ob-
servational studies, and only 1 was a clinical trial. The authors 
concluded that the strongest evidence suggesting that the 
pre-procedure INR does not likely predict the bleeding risk 
lies with central vein cannulation, although just how coagu-
lopathic patients can be and still tolerate the procedure safely 
has not been elucidated. As for the literature on the other 
procedures, the variability in study size and quality makes 
drawing firm conclusions about the bleeding risk difficult. 
In 14/25 of the studies included in the meta-analysis, a control 
group of patients with normal laboratory parameters of coag-
ulation were also included in the report. In these studies, 
the risk of bleeding between the 2 groups of patients under-
going the same procedure could be estimated [22]. Although 
the confidence intervals of some of these comparisons were 
relatively large due to the small number of patients in these 
studies, there was no significant difference in the risk of 
major bleeding between the patients who underwent these 
varied procedures with and without coagulopathies. While 
further study is required, especially for coagulopathic pa-
tients undergoing kidney biopsy, overall it would appear 
that patients with mild coagulopathies undergoing various 
surgical procedures might not require normalization of their 
laboratory coagulation parameters with plasma to reduce 
their risk of bleeding. For further discussion of why the 
PT/INR does not necessarily predict the risk of peri-operative 
bleeding, see reference [23].
  The second meta-analysis can shed some light on the ques-
tion, if plasma is administered to peri-surgical patients, does 
it have a beneficial effect in reducing transfusion require-
ments or surgical blood loss? Stanworth and colleagues 
searched various medical publication databases looking ex-
clusively for randomized controlled trials (RCT) where FFP 
was the therapeutic intervention [24]. While 57 such trials 
were identified, 19 were focused on surgical or potentially 
surgical patients; there were 11 studies based on cardiova-
scular surgery in children and adults, 3 studies on liver disease 
with or without GI bleeding, and 1 study each on warfarin 
reversal with intracerebral hemorrhage, massive transfusion, 
hip surgery, hysterectomy, and renal transplantation. In only 
12/19 of these studies (10 cardiovascular surgery, 1 liver 
disease, and the lone study on hysterectomy) did the patients 
in the control arm receive either no FFP or a colloid volume 
expander, thus allowing a true evaluation of the effect of 
the FFP administration. Most of these studies concluded 
that FFP administration did not reduce blood loss or trans-
fusion requirements [24].
  To explain why prophylactic plasma administration does 
not reduce peri-operative bleeding, consider a study of 22 
non-trauma patients who received a total of 68 units of 
FFP (500 mL units) [4]. On average each recipient received 
approximately 2 units of FFP, and this dose was ＞10 mL/kg 
for each recipient. The average pre-transfusion INR was 
1.37 (range 1.1-1.6), and the average decrease in INR was 
a clinically insignificant 0.03 per unit of FFP transfused. 
Fig. 1 demonstrates a theoretical relationship between 
PT/INR and the concentration of clotting factors; a recipient 
with INR=1.37 would likely have clotting factor concen-
trations in excess of 50% of normal (Fig. 1, point B). From 
the experience with patients with single clotting factor defi-
ciencies such as hemophilia A and B, levels of clotting factors 
＞30% are sufficient for normal hemostasis. Thus the recipi-
ents with an INR=1.37 were unlikely to have bled excessively 
even in the absence of plasma transfusion, and the slight 
reduction in INR did not confer any improvement in the 
recipient’s hemostatic potential. Furthermore, given that 
some FFP units can have INRs approaching that of these 
recipient’s [4], it is not surprising that the decreases in the 
post-transfusion INRs were quite modest.
  Abdel-Wahab and colleagues studied FFP recipients from 
a wide variety of hospital wards, and with and an assortment 
of clinical diagnoses [25]. In this retrospective study, 324 
FFP units were transfused to 121 recipients who had rela-
tively low pre-transfusion INRs, 1.1-1.85, and who had 
post-transfusion INRs performed within 8 hours of the trans-
fusion (the approximate therapeutic duration of plasma). 
Once again, only small median reductions in the post-trans-
fusion PT and INR were seen; 0.20 seconds and 0.07, 
respectively. Only 1 of the 324 recipients completely cor-
rected their PT and INR, and only 15% of patients corrected Korean J Hematol 2010;45:152-7.
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their PT/INR to 50% of normal. It is not surprising that 
patients with lower INRs (1.1-1.5) were no more likely to 
correct their coagulation parameters than those with slightly 
higher INRs (1.5-1.85), and these authors did not find a 
correlation between the magnitude of the change in the 
INR and the dose of FFP administered; recipients of 1 unit 
of FFP were no more likely to correct their INR by 50% 
than those who received 2 units [25].
  The latter finding can be explained by considering that 
1 unit of FFP (approximately 225 mL), when administered 
to a 70 kg recipient, translates into a dose of 3.2 mL/kg. 
Receipt of 2 units of FFP by a 70 kg recipient would amount 
to a dose of 6.4 mL/kg - both doses are significantly below 
the recommended 10-15 mL/kg of plasma to correct a coa-
gulopathy. Furthermore, each recipient in this study received 
on average 2.7 units of FFP, and assuming each recipient 
weighed 70 kg, the average dose of FFP would only have 
been 8.7 mL/kg [25]. Thus the low rate of correction could 
be attributable to the small volume of FFP transfused. 
Additionally, consider that the plasma volume of a 70 kg 
recipient with a Hct of 0.40 is approximately 3,000 mL. 
Transfusing 450 mL of plasma (2 regular units) would increase 
the concentration of clotting factors by 15%; according to 
Fig. 1, a 15% increase in clotting factors in a recipient with 
an INR of 1.5 would only amount to a small decrease in 
their INR (Fig. 1, point C). A recipient with an INR=1.5 
still has a considerable reserve of clotting factors and a slight 
increase in their concentration is unlikely to be important 
for hemostasis. This might also explain the popular percep-
tion of the success of prophylactically administering plasma 
to recipients with modestly elevated INRs; when these pa-
tients tolerate the surgical procedure without excessive 
bleeding, this positive outcome is attributed to the admin-
istration of the plasma. In reality, these recipients were un-
likely to have had a coagulopthic bleed owing to their sig-
nificant reserve of clotting factors (even with their slightly 
elevated INR). Another study of plasma recipients in Canada 
also found a minimal INR response when mildly coagulo-
pathic patients were transfused with small quantities of FFP 
[26].
  A study of patients with liver cirrhosis who were transfused 
with FFP was performed in 2 parts: a retrospective review 
of the charts of 80 patients who received FFP to reverse 
a PT prolonged by ＞3 seconds, and a prospective analysis 
of 20 patients who received FFP with the same laboratory 
abnormality [27]. The indications for FFP ranged from 
pre-procedure prophylaxis, acute bleeding, or prophylactic 
reversal of a prolonged PT in non-bleeding recipients. The 
etiology of the cirrhosis in the majority of these patients 
was either alcohol use or a combination of Hepatitis C and 
alcohol use. These investigators found only a small number 
of FFP recipients who corrected their PT to within 3 seconds 
of normal after FFP transfusion (12/100). Interestingly, the 
2 recipients with the highest pre-transfusion PTs who re-
ceived 6 units of (PT=23.8s and 22.9s) FFP demonstrated 
on average a 9.75s reduction in their PT after transfusion. 
The 2 recipients with the lowest PT who also received 6 
units of FFP (both had PT=15.5s) both demonstrated only 
a 0.4s reduction after transfusion [27]. While the authors 
did not convert PT into INR, a PT=15.5s roughly translates 
into an INR of approximately 1.3-1.5 depending on the sensi-
tivity of the PT reagent, once again indicating that in patients 
with a relatively mild coagulopathy, minimal correction is 
expected after plasma transfusion. 
  It might be hypothesized that the low rates of PT/INR 
correction after plasma infusion is related to the fact that 
the patients in these clinical studies have been quite sick. 
However, a different type of study evaluating the recovery 
of factor VII in normal FFP compared to a pathogen in-
activated (S-59+UVA light) form of FFP in healthy volunteers 
showed a similar magnitude of PT correction as the earlier 
studies [19]. In this study, 27 healthy volunteers donated 
approximately 2.5 L of autologous plasma over time and 
were then administered warfarin to deplete their levels of 
vitamin K-dependent clotting factors, which includes factor 
VII. After they were anticoagulated to INRs between 1.5-2.0 
they were reinfused with 1 L of either their unaltered plasma 
or their plasma after it had undergone pathogen inactivation 
after one final dose of warfarin (Fig. 2, point A). This dose 
of plasma was on average 12 mL/kg for all study participants. 
The investigators then measured a series of pharmacokinetic 
parameters of factor VII, along with a PT. Immediately prior 
to FFP administration, the average PT was 15 seconds, and 
within 1 hour after FFP administration, it had dropped to 
approximately 13 seconds (Fig. 2, point B). This 2 second 
decrease in PT represents only about 50% correction com-
pared to the average pre-anticoagulation baseline PT of 11.5 
seconds. At the end of the study period, all volunteers were 
given oral vitamin K which resulted in a complete reversal 
of their PT prolongation which should serve as a reminder 
that in situations when reversal of a coagulopathy is not 
urgent, non-human source medications such as vitamin K 
could be employed (Fig. 2, point D) [19]. Interestingly, while 
only 15% of the sick patients in the study by Abdel-Wahab 
et al. corrected their PT/INR by 50% [25], the average PT 
correction by the healthy volunteers in this study was 50% 
[19]. This 50% correction of the PT could have been predicted 
f r o m  F i g .  1 :  A g a i n ,  i f  t h e  average plasma volume of the 
healthy recipients was 3,000 mL, and they received 1,000 
mL of FFP, then their clotting factors should have been 
increased by 33%. A 33% increase in clotting factors is con-
sistent with a decrease of about 2 seconds (from 15 to 13 
seconds) (Fig. 1, from point B to D). While these healthy 
volunteers [19] received on average about 3 mL/kg more 
FFP than those reported by Abdel-Wahab et al. [25], perhaps 
other factors are involved in determining a recipient’s pro-
pensity to correct their PT/INR after plasma infusion. 
Furthermore, Holland et al. demonstrated that some patients 
with mildly prolonged INRs (1.3-1.6) will effect some degree 
of correction without plasma therapy by simply having their 
underlying diseases treated and receiving supportive care 
[28].
  Another way to consider the effect of transfusing plasma 
to patients with an elevated INR is to remember that the Korean J Hematol 2010;45:152-7.
156 Mark H. Yazer
Fig. 3. Theoretical response to plasma transfusion based on a formula 
derived from a clinical study of 140 adult plasma recipients [28]. The 
main predictor of the response to plasma transfusion is the pre- 
transfusion INR.
response of a patient who is otherwise stable (i.e., not bleed-
ing) depends mostly on the pretransfusion INR. This is de-
picted in Fig. 3 which is based on an equation derived from 
a clinical study of 140 adults who received jumbo apheresis 
plasma units (500 mL) [28]. These patients were not involved 
in trauma, not in the operating room, did not have DIC 
and were not treated with prothrombin complex concen-
trates (PCC). Clearly the largest reductions in the INR are 
predicted to occur in recipients with the highest starting 
INRs; in theory as the INR falls below 1.5, continued trans-
fusion with plasma is predicted to effect only a small and 
clinically insignificant change in the INR. At an INR≤1.5 
the recipient is being exposed to all the adverse risks of 
plasma therapy without any clinical benefit.
  Perhaps the currently employed dose of plasma to reverse 
coagulopathies is insufficient to effect a significant reduction 
in the PT/INR. A small Welsh study extensively evaluated 
the laboratory parameters of hemostasis including factor lev-
els, PT and PTT in ICU patients before and after receiving 
a median dose of either 12.2 mL/kg (n=10) or 33.5 mL/kg 
(n=12) of FFP [29]. They found much larger increases in 
the post-transfusion factor levels and decreases in the PT 
and PTT (especially the PTT) in the recipients of the higher 
dose of FFP. While this study did not investigate the clinical 
impact of higher levels of clotting factors or lower PT and 
PTT values on these recipients, it is possible that the currently 
recommended dose of 10-15 mL/kg is insufficient to reverse 
a coagulopathy [29].
CONCLUSION
  Based on clotting factor levels, FFP, TP and FP24 are 
equivalent products for reversing significant coagulopathies. 
Emerging evidence suggests that many peri-operative pa-
tients with slightly elevated PT/INRs do not suffer from 
major bleeding at a higher rate than those without coagulo-
pathies, although further study is required to delineate when 
correction is required. The generally employed threshold 
for plasma transfusion is INR≥1.6 because at higher values 
the concentrations of clotting factors begin to approach crit-
ical levels where hemostasis might be negatively affected. 
Administration of plasma to recipients with an INR≤1.5 
is unlikely to produce a clinical benefit and unnecessarily 
exposes patients to the risks of plasma transfusion. The rou-
tine administration of small quantities of plasma to peri-oper-
ative patients with minor coagulopathies probably confers 
very little hemostatic benefit and potentially subjects the 
recipients to numerous adverse reactions including volume 
overload and TRALI; conversely, higher doses of plasma 
than are currently recommended might be necessary to re-
verse a significant coagulopathy.
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